Predictors of intravenous amiodarone induced liver injury

O.A. Diab a,*, John Kamel a,1, Ahmed Adel Abd-Elhamid b,2

a Department of Cardiology, Ain Shams University Hospital, Ain Shams University, Cairo, Egypt
b Shobra General Hospital, Cairo, Egypt

Received 28 January 2016; accepted 4 May 2016
Available online 19 May 2016

Abstract Background: Intravenous (IV) amiodarone may be associated with liver injury that may necessitate drug discontinuation. The prediction of amiodarone induced liver injury (AILI) and its severity may help careful patient monitoring or the choice of other measures alternative to amiodarone in high risk patients. Little is known regarding predictors of AILI.

Objectives: To address the predictors of AILI and its severity.

Methods: The study included 180 patients indicated for IV amiodarone therapy who were divided into 2 groups: cases (90 patients) who developed AILI, and controls (90 patients) who did not develop AILI. AILI was defined as aminotransferase (ALT and AST) elevation by ≥2 folds of baseline levels. Severe AILI was defined as enzyme elevation by >5 folds of baseline values.

Results: Multivariate analysis showed that the presence of cardiomyopathy (P = 0.032), congestive hepatomegaly (P = 0.001), increasing baseline total bilirubin (P < 0.0001), direct current cardioversion (P = 0.015), and increasing dose of amiodarone (P = 0.014) to be independent predictors for AILI. Regarding severity of AILI, inotropic support (P = 0.034), congestive hepatomegaly (P = 0.012), increasing baseline total bilirubin (P = 0.001), and increasing dose of amiodarone (P = 0.002) were found to be independent predictors for severe AILI. Among cases, linear regression analysis showed that baseline ALT was the only significant independent predictor of post-amiodarone ALT (P < 0.0001), while baseline AST (P < 0.0001) and EF (P = 0.012) were the only significant independent predictors of post-amiodarone AST.

Conclusions: Compromised cardiac, hepatic, and hemodynamic conditions, with increasing dose of IV amiodarone were associated with AILI. Severity of liver injury had linear relationship with baseline aminotransferase levels and left ventricular systolic function.

1. Introduction

Drug induced liver injury (DILI) due to oral amiodarone was extensively studied. However, the available data regarding acute hepatotoxicity form intravenous (IV) amiodarone are not far beyond case reports.1-16 The mechanisms of liver injury
with IV amiodarone are controversial. Ischemic injury due to compromised hemodynamic conditions may have a role. Solubilizers in the IV amiodarone preparation such as polysorbate 80 were reported to be responsible for hepatotoxicity, possibly due to immune-mediated alteration of hepatocellular membrane. Importantly, the mechanism of injury with IV amiodarone is different from that in chronic exposure to oral therapy; therefore, acute hepatic injury following IV amiodarone does not preclude subsequent oral therapy.

Acute elevation of liver enzymes following IV amiodarone use ranged from mild asymptomatic to severe life threatening, and frequently necessitates drug discontinuation. In most of the reported cases, the liver injury occurred within 24–48 h of therapy and reversed within 2–3 weeks of discontinuation.

Parenteral amiodarone is commonly used in critically ill and hemodynamically unstable intensive care unit patients. Therefore, multiple factors may predispose patients to IV amiodarone induced liver injury (AILI). Possible predisposing factors for AILI were variably reported in different case studies. Underlying liver injury from heart failure, high dose of IV amiodarone, hypotension from ventricular arrhythmias (VAs), and postoperative therapy following coronary artery bypass grafting (CABG) were observed in case reports. Up to our knowledge, there are no prospective clinical studies that addressed the predictors of AILI.

2. Methods

The study included 180 intensive and coronary care unit patients who received IV amiodarone therapy. Patients were divided into 2 groups:

- Cases: Included 90 patients who developed AILI defined as acute rise in serum aminotransferase levels by at least 2 folds of the baseline levels within 24–48 h of IV amiodarone therapy.
- Controls: Included 90 patients who did not develop AILI.

Patients with underlying decompenated liver cell failure, hepatic coma, active hepatitis, patients with >5 fold elevation of aminotransferases relative to upper limit of normal (ULN), patients who had acute myocardial infarction (MI) within the past 3 days, and those who received multiple (>one) direct current (DC) shocks were not enrolled in the study.

2.1. Clinical assessment

Patients were subjected to history taking and physical examination emphasizing on risk factors (such as hypertension, diabetes mellitus, smoking), signs of underlying liver disease, heart failure, concomitant drug therapy.

2.2. Laboratory investigations

Before initiation of IV amiodarone therapy, liver function tests, viral markers, hemoglobin level, serum creatinine, serum sodium and potassium, INR, and random blood sugar were measured. Liver function tests and viral markers included the following:

- Aminotransferases: Baseline ALT (alanine aminotransferase) and AST (aspartate aminotransferase) were measured using standard reagents by reaction rate assay based on the conversion of NADH to NAD. Upper limit of normal (ULN) values was 44 IU/L for ALT and 34 IU/L for AST. Post-amiodarone aminotransferase levels were taken on the same day, 24, and 48 h following IV amiodarone. Peak levels were taken as post-treatment values.
- Other liver function tests included serum total and direct bilirubin (reference levels up to 1.2 and 0.3 mg/dl respectively), serum albumin (reference range 3.5 to 5.5 g/dl), and INR (international normalized ratio) that was considered high if >1.5.
- Viral markers: Included hepatitis B virus (HBV) surface antigen detected by ELISA (enzyme linked immunosorbent assay), and hepatitis C virus (HCV) antibody detected by EIA (enzyme immunoassay).

Severity AILI was graded according to rise in aminotransferase level. Due to inclusion of patients with elevated baseline aminotransferase levels, the severity grading was classified based on changes relative to their baseline value rather than ULN as follows:

- Grade 1: 1.25–2.5 folds of baseline value.
- Grade 2: 2.6–3.5 folds of baseline value.
- Grade 3: 3.6–5 folds of baseline value.
- Grade 4: >5 folds of baseline value.

2.3. Radiologic investigations

Transthoracic echocardiography was done to all patients. Left ventricular dimensions were measured by M-mode in short axis parasternal view. Left ventricular ejection fraction (EF) was calculated by M-mode in case of normal regional wall motions and by 2D (modified Simpson’s equation) in the presence of segmental wall motion abnormalities. Valve assessment including morphology, motion, transvalvular flow, and valve regurgitation was done. Structural heart disease was defined as the presence of dilated chambers, akinetic segments, low EF (<50%), or any significant (more than moderate) valve lesion. Cardiomyopathy (CM) was defined as dilated left ventricle (LV) with or without low EF.

Abdominal ultrasound was done to assess liver size and parenchyma, any abdominal fluid collection, or splenomegally. Congestive hepatomegaly was defined as increased liver size (with or without splenomegally), attributed to right sided heart failure or severe tricuspid regurge on echocardiography, with tender hepatomegaly and hepatojugular reflux on physical examination.

2.4. Amiodarone therapy and in-hospital course

Amiodarone was given by IV loading of 5 mg/kg as a 30 min IV infusion, followed by infusion of 10 mg/kg/day over 24–48 h. Indication of therapy was documented by 12-lead surface electrocardiogram (ECG). The duration, total dose received, and the need of amiodarone discontinuation were recorded. Causes of discontinuation included significant liver injury defined as >10 fold rise in aminotransferases relative to ULN, hemodynamically significant bradyarrhythmias, ineffec-
Amiodarone Induced Liver Injury

47

2.5. Statistical analysis

Statistical Package for Social Sciences (SPSS, Inc, version 21, Chicago, IL) was used. D’Agostino–Pearson test was used to ascertain normality of continuous data distribution. Categorical data were expressed as frequencies, while continuous data were expressed as mean ± SD or median according to data distribution. Comparison between categorical variables was done using Chi square or Fisher’s exact test as appropriate. Comparison between continuous variables was done using unpaired t-test or Mann–Whitney test as appropriate. Predictors of AILI and severe (grade 4) AILI were listed in logistic regression models. Clinically relevant or variables with <0.1 significance on univariate analysis were further tested in multivariate models with conditional backward method. ROC curve analysis was used to find a cutoff value for continuous variables found to be significant predictors on multivariate analysis. Linear regression analysis was used to find predictors of post-amiodarone aminotransferases. Correlations with post-amiodarone transaminases were done using Spearman’s rho. P value was considered significant if < 0.05.

3. Results

3.1. Baseline characteristics

Baseline characteristics and comparison between cases and controls are shown in Table 1. All patients had baseline aminotransferase levels < 5 folds of ULN before initiating amiodarone therapy. None of the studied patients was alcohol user. Cases had more frequent male gender (P = 0.017), underlying structural heart disease (predominantly cardiomyopathy, P = 0.024), chronic liver disease (predominantly congestive hepatomegaly, P < 0.0001), and +ve viral markers (predominantly HCV, P = 0.026) than controls. Inotropic support was more frequent in cases than in controls with borderline significance. Baseline AST (P = 0.022), total bilirubin (P < 0.0001), direct bilirubin (P < 0.0001), and serum creatinine (P = 0.016) were higher, while serum albumin (P = 0.002) was lower in cases than in controls.

3.2. Amiodarone therapy and in-hospital course

Indications of IV amiodarone therapy varied between atrial fibrillation (AF), supraventricular tachycardia (SVT), and ventricular arrhythmias (VAs) with no difference between cases and controls (Table 2). Discontinuation rate was 26.6% for the whole study population, 52.2% among cases, and 1.1% among controls. The main cause of discontinuation was liver enzyme elevation. Among cases, IV amiodarone was initiated in 16 patients following CPR from cardiac arrest due to VAs, and all received DC cardioversion, while in controls, CPR was done to 6 patients (P = 0.023), 3 of whom received DC cardioversion before amiodarone therapy (P = 0.002). There were no significant differences between cases and controls regarding a number of patients who developed hepatic coma (although more in cases than in controls) and in-hospital deaths within 48 h of amiodarone therapy.

3.3. Predictors of AILI

Univariate logistic regression analysis with AILI as dependent variable and each of the variables shown in Table 3 as independent variables, showed that male gender, underlying CM, congestive hepatomegaly, +ve viral markers, increasing baseline total and direct bilirubin, lower serum albumin, increasing random blood sugar, CPR, and DC cardioversion were found to be significant predictors of AILI.

On multivariate analysis, male gender, CM, inotropic support, congestive hepatomegaly, +ve viral markers, baseline transaminases, total and direct bilirubin, serum albumin, random blood sugar, CPR, DC cardioversion, and dose of amiodarone were listed as independent variables in a logistic regression model. Backward-conditional method retained the presence of CM (P = 0.032), congestive hepatomegaly (P = 0.001), increasing baseline total bilirubin (P < 0.0001), DC cardioversion (P = 0.015), and increasing dose of amiodarone (P = 0.014) as independent predictors for AILI.

Continuous variables found to be significant predictors for AILI on multivariate analysis (baseline total bilirubin and dose of amiodarone) were further tested in a ROC curve. ROC curve analysis (Fig. 1A) showed that a total bilirubin > 1.3 mg/dl could predict AILI with a sensitivity and specificity of 64.4% and 77.8% respectively (AUC: 0.72, 95% CI: 0.64–0.79, P < 0.0001). Regarding dose of amiodarone, ROC curve analysis did not show a significant cutoff value (AUC: 0.54, 95% CI: 0.46–0.63, P = 0.25).

3.4. Predictors of severe AILI

Among patients with AILI (90 patients), grades 1, 2, 3, and 4 liver injury occurred in 0 (0%), 1 (1.1%), 19 (21.1%), and 70 (77.8%) patients (mean grade: 3.76 ± 0.45). In grade 4 AILI, mean rise of ALT and AST was 8.53 ± 4.33 and 7.67 ± 5.12 folds from baseline respectively.

Among the whole study population, univariate logistic regression analysis with severe (grade 4) AILI as dependent variable and each of the variables shown in Table 4 as independent variables showed that inotropic support, congestive hepatomegaly, increasing baseline total and direct bilirubins, lower serum albumin, and increasing dose of amiodarone were found to be significant predictors for severe AILI.

On multivariate analysis, inotropic support, congestive hepatomegaly, +ve viral markers, total and direct bilirubins, serum albumin, random blood sugar, DC cardioversion, and dose of amiodarone were listed as independent variables in a logistic regression model. Backward-conditional method retained inotropic support (P = 0.034), congestive hepatomegaly (P = 0.012), increasing baseline total bilirubin (P = 0.001), and increasing dose of amiodarone (P = 0.002) as independent predictors for severe AILI.

Continuous variables found to be significant predictors for severe AILI on multivariate analysis (baseline total bilirubin and dose of amiodarone) were further tested in a ROC curve.
Table 1  Baseline characteristics and comparison between cases and controls.

|                      | All   | Cases  | Controls | P value |
|----------------------|-------|--------|----------|---------|
|                      | N= 180| N= 90  | N= 90    |         |
| Age (years)          | 62.78 ± 12.78 | 63.65 ± 12.3 | 61.92 ± 13.25 | 0.36    |
| Sex (M, F)           | 92, 88 | 54, 36 | 38, 52   | 0.017   |
| Risk factors         |       |        |          |         |
| DM                   | 107   | 52     | 55       | 0.64    |
| HTN                  | 123   | 61     | 62       | 0.87    |
| Dyslipidemia         | 55    | 29     | 26       | 0.62    |
| Smoking              | 65    | 36     | 29       | 0.27    |
| Structural heart disease | 90  | 52     | 38       | 0.037   |
| IHD                  | 93    | 43     | 50       | 0.29    |
| RHD                  | 12    | 5      | 7        | 0.55    |
| CM                   | 79    | 47     | 32       | 0.024   |
| AF/flutter            | 88    | 41     | 47       | 0.37    |
| Statin use           | 56    | 26     | 30       | 0.52    |
| Warfarin use         | 23    | 9      | 14       | 0.26    |
| Antimicrobials       | 133   | 70     | 63       | 0.23    |
| Inotropic support    | 15    | 11     | 4        | 0.05    |
| Chronic liver disease | 93   | 56     | 37       | 0.005   |
| Congestive hepatomegaly | 47  | 36     | 11       | <0.0001 |
| Cirrhotic changes    | 46    | 20     | 26       | 0.39    |
| Viral markers        |       |        |          |         |
| +ve/−ve              | 45/135| 50/60  | 15/75    | 0.01    |
| HBV                  | 2     | 1      | 1        |         |
| HCV                  | 38    | 24     | 14       | 0.026   |
| Both HBV and HCV     | 5     | 5      | 0        |         |
| EF (%)               | 45.93 ± 12.39 | 46.54 ± 13.64 | 45.33 ± 11 | 0.51    |
| EF < 40%             | 54    | 32     | 22       | 0.11    |
| LVEDD (mm)           | 56.33 ± 9.5 | 56.2 ± 9.16 | 56.46 ± 9.88 | 0.85    |
| LVESD (mm)           | 41.03 ± 9.98 | 40.56 ± 9.89 | 41.5 ± 9.9 | 0.52    |
| TR                   |       |        |          |         |
| Normal TV            | 88    | 42     | 46       |         |
| Mild/moderate        | 69    | 35     | 34       | 0.74    |
| Severe               | 23    | 13     | 10       |         |
| MVD                  |       |        |          |         |
| Normal MV            | 43    | 20     | 23       |         |
| Mild/moderate        | 126   | 61     | 65       | 0.09    |
| Severe               | 11    | 9      | 2        |         |
| AVD                  |       |        |          |         |
| Normal AV            | 111   | 59     | 52       | 0.24    |
| Mild/moderate        | 67    | 31     | 36       |         |
| Severe               | 2     | 0      | 2        |         |
| Baseline laboratory tests |     |        |          |         |
| ALT (IU/L)           | 29.94 ± 20.04 (median 23) | 32.44 ± 21.97 (median 26) | 27.44 ± 17.68 (median 21) | 0.14 |
| AST (IU/L)           | 37.61 ± 22.54 (median 30) | 40.96 ± 25.31 (median 35.5) | 34.26 ± 18.95 (median 28.5) | 0.022 |
| Total bilirubin (mg/dl) | 1.71 ± 2.16 (median 1.2) | 2.27 ± 2.87 (median 1.7) | 1.15 ± 0.72 (median 0.9) | <0.0001 |
| Direct bilirubin (mg/dl) | 0.82 ± 1.67 (median 0.5) | 1.15 ± 2.25 (median 0.8) | 0.48 ± 0.57 (median 0.3) | <0.0001 |
| Albumin (g/dl)       | 3.15 ± 0.65 | 3.01 ± 0.7 | 3.3 ± 0.57 | 0.002 |
| INR                  | 1.72 ± 1.38 (median 1.35) | 1.79 ± 1.02 (median 1.4) | 1.64 ± 1.67 (median 1.3) | 0.08 |
| Creatinine (mg/dl)   | 2.33 ± 3.23 (median 1.4) | 2.42 ± 2.36 (median 1.7) | 2.24 ± 3.93 (median 1.15) | 0.016 |
| Na⁺ (mEq/L)          | 135.96 ± 9.46 (median 136) | 135.02 ± 11.47 (median 135) | 136.91 ± 6.82 (median 137) | 0.069 |
| K⁺ (mEq/L)           | 4.08 ± 0.96 (median 4) | 4.03 ± 1.12 (median 3.9) | 4.14 ± 0.77 (median 4.1) | 0.19 |
| Hb (gm%)             | 10.27 ± 2.18 | 10.17 ± 2.28 | 10.38 ± 2.09 | 0.52 |
| Random sugar (mg/dl) | 210.1 ± 101.73 (median 192.5) | 226.93 ± 121.3 (median 207.5) | 193.26 ± 74.35 (median 190) | 0.15 |

M: Male, F: Female, DM: Diabetes Mellitus, HTN: Hypertension, IHD: Ischemic heart disease, RHD: Rheumatic heart disease, CM: Cardiomyopathy, AF: Atrial fibrillation, HSM: Hepatosplenomegaly, HBV: Hepatitis B virus, HCV: Hepatitis C virus, EF: Ejection fraction, LVEDD: Left ventricular end diastolic diameter, LVESD: Left ventricular end systolic diameter, TR: Tricuspid regurge, MVD: Mitral valve disease, AVD: Aortic valve disease, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase and Hb: Hemoglobin.
Table 2  Comparison between cases and controls regarding amiodarone therapy and in-hospital course.

| Indication                  | Cases N = 90 | Controls N = 90 | P value |
|-----------------------------|--------------|-----------------|---------|
| Indication                  |              |                 |         |
| AF                          | 48           | 50              | 0.93    |
| SVT                         | 21           | 19              | 0.03    |
| VAs                         | 21           | 21              | 0.03    |
| Dose received (mg)          | 1198.33 ± 368.45 (median 1200) | 1116.66 ± 238.08 (median 1200) | 0.13 |
| Duration (h)                | 27.33 ± 15.88 (median 24) | 24.28 ± 6.2 (median 24) | 0.64 |
| Discontinuation             |              |                 |         |
| Elevated liver enzymes      | 46           | 0               |         |
| Bradycardia                 | 1            | 0               | <0.0001 |
| Ineffectiveness             | 0            | 1               |         |
| QTc interval prolongation    | 0            | 0               |         |
| Post-amiodarone ALT (IU/L)  | 199.05 ± 117.5 (median 169.5) | 29.63 ± 16.55 (median 25) | <0.0001 |
| ALT rise (folds of baseline values) | 7.51 ± 4.28 | 1.16 ± 0.38 | <0.0001 |
| Post-amiodarone AST (IU/L)  | 229.82 ± 102.76 (median 200.5) | 39.02 ± 20.5 (median 31.5) | <0.0001 |
| AST rise (folds of baseline values) | 6.82 ± 4.8 | 1.2 ± 0.45 | <0.0001 |
| Hepatic coma                | 3            | 1               | 0.62    |
| CPR                         | 16           | 6               | 0.023   |
| DC shock                    | 16           | 3               | 0.002   |
| Death                       | 9            | 10              | 0.8     |

AF: Atrial fibrillation, SVT: Supraventricular tachycardia, VAs: Ventricular Arrhythmias, QTc: Corrected QT interval, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CPR: Cardiopulmonary resuscitation and DC: Direct current.

Table 3  Predictors of amiodarone induced liver injury on univariate and multivariate logistic regression analyses.

|                      | OR     | 95% CI       | P value | Univariate | OR     | 95% CI       | P value |
|----------------------|--------|--------------|---------|------------|--------|--------------|---------|
| Male gender          | 2.05   | 1.13–3.71    | 0.018   | –          | 2.19   | 1.06–4.49    | 0.032   |
| CM                   | 1.98   | 1.09–3.6     | 0.025   | –          | 4.24   | 1.81–9.93    | 0.001   |
| Inotropic support    | 2.99   | 0.91–9.78    | 0.07    | –          | 4.78   | 2.24–10.22   | <0.0001 |
| Congestive hepatomegaly | 4.78  | 2.24–10.22   | <0.0001 | –         | 4.78   | 2.24–10.22   | <0.0001 |
| +ve viral markers    | 2.5    | 1.23–5.06    | 0.011   | –          | 6.82   | 1.2 ± 0.45   | <0.0001 |
| Increasing baseline ALTa | 1.01 | 0.99–1.02    | 0.09    | –          | 1.01   | 1–1.02       | 0.053   |
| Increasing baseline ASTa | 2.44 | 1.62–3.67    | <0.0001 | –         | 2.44   | 1.62–3.67    | <0.0001 |
| Increasing baseline T. bilirubina | 2.86 | 1.66–4.91    | <0.0001 | –         | 2.86   | 1.66–4.91    | <0.0001 |
| Low baseline s. albumin c | 2.05 | 1.27–3.3     | 0.003   | –          | 2.05   | 1.27–3.3     | 0.003   |
| Increasing s. creatinineb | 1.01 | 0.92–1.11    | 0.7     | –          | 1.01   | 0.92–1.11    | 0.7     |
| Increasing random sugarb | 1.033 | 1.17       | 0.029   | –          | 1.003  | 1.17       | 0.029   |
| Low EFd               | 1.008  | 0.98–1.03    | 0.51    | –          | 1.008  | 0.98–1.03    | 0.51    |
| CPR                  | 3.02   | 1.12–8.13    | 0.028   | –          | 3.02   | 1.12–8.13    | 0.028   |
| DC shock             | 6.27   | 1.75–22.3    | 0.005   | 5.83       | 5.83   | 1.4–24.2     | 0.015   |
| Increasing dose of amiodaronec | 1.001 | 1–1.003     | 0.087   | 1.002     | 1.002 | 1–1.003     | 0.014   |

OR: Odds ratio, CI: Confidence interval, CM: Cardiomyopathy, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, T. bilirubin: Total bilirubin, D. bilirubin: Direct bilirubin, EF: Ejection fraction, CPR: Cardiopulmonary resuscitation and DC: Direct current.

ROC curve analysis (Fig. 1B) showed that a total bilirubin >1.6 mg/dl can predict severe AILI with a sensitivity and specificity of 52.9% and 77.3% respectively (AUC: 0.67, 95% CI: 0.6-0.74, P < 0.0001). Regarding dose of amiodarone, ROC curve analysis did not show a significant cutoff value (AUC: 0.55, 95% CI: 0.47-0.64, P = 0.2).

3.5. Correlations with post-amiodarone aminotransferases among cases

Among patients with AILI (90 cases), post-amiodarone ALT and AST were significantly correlated with each of baseline ALT, AST, total bilirubin, direct bilirubin, and EF (Table 5, ...
Post-amiodarone AST, but not ALT, was significantly correlated with LVEDD and LVESD.

Stepwise linear regression analysis with post-amiodarone ALT and AST as dependant outcomes and baseline ALT, AST, total and direct bilirubins, and EF as independent variables showed that baseline ALT was the only significant independent predictor of post-amiodarone ALT ($P < 0.0001$), while baseline AST ($P < 0.0001$) and EF ($P = 0.012$) were the only significant independent predictors of post-amiodarone AST.

4. Discussion

Identifying the predictors of IV amiodarone induced liver injury (AILI) may help close patient monitoring or the choice of other measures alternative to amiodarone in high risk patients. While risk factors of liver injury with oral amiodarone were previously characterized, little is known regarding IV amiodarone.

In the current study, the presence of CM, congestive hepatomegaly, increasing baseline total bilirubin, DC shock, and increasing dose of amiodarone were significantly associated with severe amiodarone induced liver injury.
cardioversion, and increasing dose of amiodarone were found to be independent predictors for AILI on multivariate analysis. We demonstrated that underlying CM, congestive hepatomegaly, and DC cardioversion increased the possibility (or odds) of having AILI by 2, 4, and 5 folds respectively, and every 1 mg/dl increase in baseline total bilirubin raised the possibility of having AILI by about 3 fold. We also demonstrated that every 1 mg increase in amiodarone dose raised the odds of having AILI by 1.002 fold (i.e. 1.9 fold in a dose of 450 mg) which means that the possibility of liver injury almost doubles with every 12 hours of IV amiodarone therapy. Similarly, heart failure, congestive liver disease, high dose of IV amiodarone, and hypotension from ventricular arrhythmias were observed in patients with AILI among case reports.4,18,19

Liver injury was found to be severe in the majority (77.8%) of our cases as well as most of the case reports, indicating that injury might follow “all or none” phenomenon. This can also explain that the predictors of severe AILI in our study were similar to those of AILI. However, in a retrospective study, Huang et al.23 reported that liver injury was mild in 92 out of 101 patients with IV amiodarone induced hepatotoxicity. Two reasons were likely behind this discrepancy; the first is the difference in defining the severity of liver injury (they

### Table 5  Variables correlated with post-amiodarone aminotransferases.

| Variable                  | Post-amiodarone ALT | Post-amiodarone AST |
|---------------------------|---------------------|---------------------|
| Age                       | Correlation coefficient  | 0.12                | 0.17                |
|                           | P value              | 0.25                | 0.1                 |
| Baseline ALT              | Correlation coefficient  | 0.62                | 0.48                |
|                           | P value              | <0.0001             | <0.0001             |
| Baseline AST              | Correlation coefficient  | 0.41                | 0.53                |
|                           | P value              | <0.0001             | <0.0001             |
| Baseline T. bilirubin     | Correlation coefficient  | 0.34                | 0.29                |
|                           | P value              | 0.001               | 0.005               |
| Baseline D. bilirubin     | Correlation coefficient  | 0.31                | 0.29                |
|                           | P value              | 0.003               | 0.005               |
| Baseline s. albumin       | Correlation coefficient  | -0.12               | -0.09               |
|                           | P value              | 0.23                | 0.39                |
| S. creatinine             | Correlation coefficient  | -0.05               | 0.005               |
|                           | P value              | 0.58                | 0.96                |
| Random sugar              | Correlation coefficient  | 0.05                | 0.15                |
|                           | P value              | 0.64                | 0.13                |
| Hemoglobin                | Correlation coefficient  | 0.07                | 0.02                |
|                           | P value              | 0.49                | 0.81                |
| EF                        | Correlation coefficient  | -0.22               | -0.36               |
|                           | P value              | 0.037               | <0.0001             |
| LVEDDD                    | Correlation coefficient  | 0.15                | 0.28                |
|                           | P value              | 0.15                | 0.007               |
| LVESD                     | Correlation coefficient  | 0.13                | 0.24                |
|                           | P value              | 0.2                 | 0.022               |
| Dose of amiodarone        | Correlation coefficient  | -0.09               | -0.14               |
|                           | P value              | 0.35                | 0.16                |

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, T. bilirubin: Total bilirubin, D. bilirubin: Direct bilirubin, EF: Ejection fraction, LVEDD: Left ventricular end diastolic diameter and LVESD: Left ventricular end systolic diameter.

* All correlations were done using Spearman’s rho.
defined severe injury as ALT > 10 folds of ULN in their study). The second reason is the incomplete amiodarone dosing regimen given in 55.7% of their study population in the form of either loading without maintenance or maintenance without loading. Furthermore, the loading dose in their study was much lower than that recommended by guidelines. Although they studied a large number of patients, they did not include baseline liver functions, abdominal ultrasound, or echocardiographic measures in their analysis. However, they found that male gender was a risk factor for IV amiodarone induced hepatotoxicity which was similar to what we observed on univariate analysis. The same was also reported with oral amiodarone.24

In the present study, baseline total bilirubin was a highly significant predictor for AILI and severe AILI. A total bilirubin >1.3 mg/dl could predict AILI, while a serum level >1.6 mg could predict severe AILI with low sensitivity but higher specificity. In a similar context, total bilirubin was found to be a significant predictor for drug induced liver injury (DILI) in general, and a cutoff level ≥1.0 mg/dL was associated with high risk of acute liver failure.25 High serum bilirubin is associated with hepatic decompensation and was solely found to be a prognostic marker in patients with chronic liver disease in which aminotransferases may be mildly elevated.26 We observed that baseline ALT and AST were significant predictors for severity of liver injury on linear regression analysis. High baseline aminotransferases were also associated with high risk of acute liver failure in patients with DILI.25 We demonstrated that hemodynamic state might predispose liver to AILI. While the presence of cardiomyopathy and the need for DC cardioversion due to VAs could predict AILI, the need for inotropic support was associated with severe AILI. The debate around liver hypoperfusion whether or not to be the actual cause of injury associated with IV

---

**Figure 2** Correlations with post-amiodarone aminotransferases, showing significant correlations with each of baseline ALT (A), AST (B), total bilirubin (C), and ejection fraction (D).
amiodarone \(^{5,6,16}\) demanded a case control study with multivariate analysis. Since we found other factors to be independently associated with AILI, the link between liver hypoperfusion and AILI is likely to be a predisposition rather than a causal relationship.

Underlying cardiac condition was related to AILI in the present study in two aspects. The presence of CM was a significant predictor for its occurrence on logistic regression, and the EF was a significant predictor for its severity on linear regression. This was in accordance with several case studies in which LV dysfunction was observed. \(^{4,7,12,18,19}\) The same was also found with oral amiodarone. \(^{22}\) If direct drug toxicity is assumed, LV dysfunction delays amiodarone elimination by prolonging the half life of its metabolites, and therefore might predispose to liver injury. \(^{7}\)

We summarized the predictors of AILI and its severity in Fig. 3 based on our findings. In high risk patients, we recommend that benefit of IV amiodarone should be weighed against its possible hazard, especially in non-life threatening conditions such as atrial fibrillation.

5. Conclusions

Parenteral amiodarone induced liver injury (AILI) and its severity could be predicted by underlying heart disease (cardiomyopathy, low EF), liver disease (congestive hepatomegaly, elevated bilirubin and aminotransferases), hemodynamic instability (DC cardioversion, inotropic support), and increasing dose of amiodarone.

Conflict of interests

The authors have no conflict of interests to disclose.

References

1. Agozzino F, Picca M, Pelosi G. Acute hepatitis complicating intravenous amiodarone treatment. \emph{Ital Heart J} 2002;3:686–8.
2. Chan AL, Hsieh HJ, Hsieh YA, Lin SJ. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. \emph{Int J Clin Pharmacol Ther} 2008;46:96–101.
3. Rätz Bravo AE1, Drewe J, Schlienger RG, Krähenbühl S, Pargger W, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. \emph{Crit Care Med} 2005;33:128–34.
4. Rao U, Agrawal A. Amiodarone-induced acute hepatotoxicity. \emph{Eur J Clin Pharmacol} 2012;68:449–50.
5. Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity likely due to ischemic hepatitis. \emph{Isr Med Assoc J} 2011;13:748–52.
6. Lahbabi M, Aqodad N, Ibrahimi A, Lahlou M, Aqodad H. Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. \emph{World J Hepatol} 2012;4:196–8.
7. Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCallough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. \emph{Drug Healthc Patient Saf} 2013;5:191–8.
8. Thiele RH, Williams J, Moylan CA, Rao SV, Bennett-Guerrero E. \emph{CASE} 6–2012: suspected amiodarone hepatotoxicity after cardiac surgery. \emph{J Cardiothorac Vasc Anesth} 2012;26:729–32.
9. Kicker JS, Haizlip JA, Buck ML. Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant. \emph{J Pediatr Pharmacol Ther} 2012;17:189–95.
10. Grecian R, Ainslie M. Acute hepatic failure following intravenous amiodarone. \emph{BMJ Case Rep} 2012. \url{http://dx.doi.org/10.1136/bcr-2012-007080}.
11. von Vital JM, Karachristos A, Singhal A, Thomas R, Jain A. Acute amiodarone hepatotoxicity after liver transplantation. \emph{Transplantation} 2011;91:e624–6.
12. Verhovez A, Elia F, Riva A, Ferrari G, Aprà F. Acute liver injury after intravenous amiodarone: a case report. \emph{Am J Emerg Med} 2011;29:843.
13. Cataldi A, Gonella D, Robutti N, Siri M, Buonocore S, Odetti P. Hepatotoxicity after intravenous amiodarone. \emph{Aging Clin Exp Res} 2008;20:593–6.
14. Rizzoli E, Incasa E, Gamberini S, Savelli S, Zangirilami A, Tampieri M, et al. Acute toxic hepatitis after amiodarone intravenous loading. \emph{Am J Emerg Med} 2007;25:1082.
15. Maker AV, Orgill DP. Rapid acute amiodarone-induced hepatotoxicity in a burn patient. \emph{J Burn Care Rehabil} 2005;26:341–3.
16. Stratton A, Fenderson J, Penny P, Helman DL. Severe acute hepatitis following intravenous amiodarone: a case report and review of the literature. \emph{Acta Gastroenterol Belg} 2015;78:233–9.
17. Gregory SA, Webster JB, Chapman GD. Acute hepatitis induced by parenteral amiodarone. \emph{Am J Med} 2002;113:254–5.
18. Pye E, Northcote RJ, Cobbe SM. Acute hepatitis after parenteral amiodarone administration. \emph{Br Heart J} 1988;59:690–1.
19. Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? \emph{Gut} 1993;34:565–6.
20. Huang XJ, Choi YK, Im HS, Yarimaga O, Yoon E, Kim HS. Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) during amiodarone therapy. \emph{J Korean Med Sci} 2007;22:992–7.
21. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74–80.

22. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995;35:351–6.

23. Huang X, Yang Y, Zhu J, Gao X, Wang G, Tan H, et al. Clinical applications and acute hepatotoxicity of intravenous amiodarone. J Intern Med Res 2009;37:1928–36.

24. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679–85.

25. Lo Re 3rd V, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol 2015;13:2360–8.

26. López-Velázquez JA, Chávez-Tapia NC, Ponciano-Rodríguez G, Sánchez-Valle V, Caldwell SH, Uribe M, et al. Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. Ann Hepatol 2013;13:98–104.